Jubilant Pharma Limited, a wholly-owned subsidiary of
Jubilant Pharmova Limited, on Monday announced a US$92 Mn investment to expand sterile injectable manufacturing capacity at its Spokane site in Washington, US. This investment is being made to set up a high-speed 400 vials a minute injectable fill line with isolator technology, which will enhance the Spokane facility’s capacity by 50%, the company said in the filing.
This expansion will also include two 300 sq feet Lyophilizers. This expansion will be spread over 50,000 sq feet at the Spokane facility and will be commercially operational by the end CY24.
Jubilant Pharmova Limited stock was unded pressure at Rs847.15 per piece down Rs24.55 or 2.82% on the BSE after touching a day's high of Rs884.90 per piece early on Tuesday.
“We are excited to expand our sterile injectable and vaccine manufacturing capacity and meet the increasing demand from our customers,” said Amit Arora, President Jubilant HollisterStier.
“We are pleased to announce the planned expansion of the sterile injectable manufacturing capacity at this critical juncture. With two facilities in North America working to manufacture multiple Covid-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic and are prepared for a potential future pandemic response. This expansion will also help us meet high demand from our global Specialty Pharmaceutical customers, with whom the company has established strong relationships” stated Pramod Yadav, CEO Jubilant Pharma Limited.